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Novelty Statement: 
 A simple cost-utility model was developed to evaluate new interventions for 
Type 1 diabetes mellitus by assessing the association between the 
interventions’ effects on mean glycated haemoglobin and long-term 
complications and the risk of hypoglycaemic events. 
 High-quality, recently reported data specific to people with Type 1 diabetes 
mellitus were identified by a systematic review. 
 Model validation included review by clinical and economic experts, verification 
of input data and formulae, and comparison of model predictions with 
observations from studies used to build the model and other published data. 
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ABSTRACT 
Aims: To develop a health economic model to evaluate the cost-effectiveness of new 
interventions for Type 1 diabetes mellitus (Type 1 DM) by their effects on long-term 
complications (measured through mean glycated haemoglobin) while capturing the impact of 
treatment on hypoglycaemic events. 
Methods: Through a systematic review, we identified complications associated with 
Type 1 DM and data describing the long-term incidence of these complications. An individual 
patient simulation model was developed and included the following complications: 
cardiovascular disease, peripheral neuropathy, microalbuminuria, end-stage renal disease, 
proliferative retinopathy, ketoacidosis, cataract, and adverse birth outcomes. Risk equations were 
developed from published cumulative incidence data and hazard ratios for the effect of glycated 
haemoglobin, age, and duration of diabetes. We validated the model by comparing model 
predictions with observed outcomes from studies used to build the model (internal validation) 
and from other published data (external validation). We performed illustrative analyses for 
typical patient cohorts and a hypothetical intervention. 
Results: Model predictions were within 2% of expected values in the internal validation 
and within 8% of observed values in the external validation  (percentages represent absolute 
differences in the cumulative incidence). 
Conclusions: The model utilised high-quality, recent data specific to people with Type 1 
DM. In the model validation, results deviated less than 8% from expected values. 
Key words: diabetes mellitus, type 1; models, economic, economics, medical; costs and 
cost analysis 
 4 
INTRODUCTION 
Since the Diabetes Control and Complications Trial (DCCT) established that intensive 
therapy slows the progression of Type 1 diabetes mellitus (Type 1 DM) complications [1], a 
number of new blood glucose management interventions have been developed. Evaluation of the 
value for money associated with new interventions is needed to assist decision makers in the 
efficient allocation of health care resources. Because the costs and quality-of-life impairments 
resulting from Type 1 DM complications develop over several decades, an economic model is 
needed. Until recently, economic models providing analyses for Type 1 DM had been designed 
primarily for Type 2 DM and did not include recent, systematically identified data specific to 
Type 1 DM [2]. 
Our objective was to develop a transparent cost-utility model in line with good practice 
guidelines [3] specifically for new Type 1 DM interventions. This article presents the model 
design and validation and the example results for a hypothetical intervention. The model 
structure and input data were based on a systematic review [4] and guided by a clinical expert. 
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PATIENTS AND METHODS 
The model simulated costs and outcomes over the lifetimes of a hypothetical cohort of 
people in the United Kingdom (UK) with Type 1 DM (as defined by the World Health 
Organization; see Supporting Information). The population characteristics (Table S1) and all 
model parameters and sources are presented in the Supporting Information. 
The base-case analysis was conducted from the perspective of the UK’s National Health 
Service and Personal Social Services and included costs associated with hospital care, primary 
care, and social care. Total government and societal perspectives also could be evaluated. 
Treatments and Treatment Effects 
To compare an intervention of interest versus a control intervention, treatment effects are 
entered into the model as differences in glycated haemoglobin (HbA1c) and rates of 
hypoglycaemia (as measured in trials). HbA1c levels are used in the model to predict the 
incidence of Type 1 DM complications over peoples’ lifetimes. Annual treatment costs also are 
entered into the model; people were assumed to continue on the assigned treatment for the entire 
model timeframe. 
Model Structure 
An individual patient simulation model with 1-year cycle was programmed in Microsoft 
Excel (Fig. 1). At the start of the model, the characteristics of individual patients were sampled 
from the population characteristics (Table S1). During each model year, people could develop 
complications or could die of a complication or other causes. Trends in HbA1c over time were 
not included because HbA1c levels are relatively stable in Type 1 DM [5] (see Supporting 
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Information). Total costs, life-years, and QALYs accrued over the analysis timeframe were 
calculated and discounted at a rate of 3.5% per annum [6]. 
Complications of Type 1 DM were identified by a systematic review [4]. Complications 
were included in the model where there was evidence for a statistical association between 
Type 1 DM, HbA1c, and an impact on mortality, costs, and/or health-related quality of life 
(Table S2). The following complications were selected: cardiovascular disease, peripheral 
neuropathy, renal disease, retinopathy, cataract, hypoglycaemia, and ketoacidosis. The risk of 
stillbirth, perinatal mortality, and infant congenital malformation are substantially increased with 
Type 1 DM [7]. Therefore, the model included an optional analysis of life-years and quality-
adjusted life-years (QALYs) lost due to infant death or congenital malformation. 
Prediction of Disease Progression and Death 
Data describing the development of complications over time were identified by the 
systematic review; 281 publications reporting 72 unique studies were identified. Because the 
model performs analyses over people’s lifetimes, data from long-term follow-up studies 
describing the development of complications over several decades were preferred. However, 
long-term studies are unlikely to accurately represent outcomes in current clinical practice 
because of improvements in Type 1 DM management. The DCCT and the follow-up 
Epidemiology of Diabetes Interventions and Complications (EDIC) study provide more than 
20 years of follow-up in a cohort who received intensive HbA1c control (e.g., [1]). These studies 
were used, where possible, to estimate the underlying risk of complications. Other studies were 
used for validation, and the effects of HbA1c were summarised from all studies so that 
alternative values could be explored. 
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With the exception of hypoglycaemia and pregnancy outcomes, development of 
complications was governed in the model by time-dependent probabilities derived from 
parametric functions (shown as ellipses in #Fig. 1) fitted to published cumulative incidence 
curves. Data from published curves were estimated electronically (Digitize Software; DigitizeIt 
1.5, Köln, Germany). Parametric functions were fitted using the Solver function in Excel and 
individually selected for each complication based on minimising the sum squared of residuals, 
visual goodness of fit, and clinical plausibility of long-term predictions. Each function was 
adjusted for the effects of HbA1c and other risk factors, using published hazard ratios, (Table 1). 
Risk factors were limited to age and duration of diabetes, due to the limitations of available data. 
The development of subsequent complications (e.g., death from cardiovascular disease, 
conditional upon a first event) was governed by fixed probabilities. 
A summary of the remaining model parameters is presented in Table S3. An overview of 
the modelling approach for each complication is provided in the following subsections. 
[FIG. 1 HERE] 
Cardiovascular Disease 
Probabilities of a first cardiovascular event were derived from a Weibull function fitted to 
data from the DCCT and EDIC studies (Table 1 [1]). The type of first event was specified (death, 
non-fatal acute myocardial infarction, silent myocardial infarction, revascularisation, confirmed 
angina, or non-fatal cerebrovascular event), using conditional probabilities based on the type of 
first event observed. The probabilities of subsequent events also were based on the DCCT and 
EDIC studies, with the exception of stroke (where no subsequent events were observed). The risk 
of death from cardiovascular complications was not available for people with Type 1 DM; 
probabilities were based on data for general cardiovascular patients. 
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Cataract and Cataract Surgery 
Probabilities of cataract surgery were calculated from a Weibull function (Table 1 [8]). 
People were assumed to have clinically significant visual impairment for 1 year prior to cataract 
surgery [9]. Up to two cataract surgeries were modelled. 
Peripheral Neuropathy (Foot Ulcer and Lower Extremity Amputation) 
Probabilities of peripheral neuropathy were derived from a Weibull function fitted to data 
from the DCCT and EDIC studies (Table 1 [10]). 
Neuropathy-related conditions, such as erectile dysfunction, urinary incontinence, and 
urinary tract infections, were excluded from the model because there was insufficient evidence 
that effective diabetes management reduced their risk. 
Probabilities of diabetic foot ulcer, amputation (conditional upon having peripheral 
neuropathy), gangrene and infection for people with a foot ulcer, and the probabilities of peri-
operative death for people with lower-extremity amputation are presented in Table S3. Up to two 
lower-extremity amputations per patient were modelled. 
People with peripheral neuropathy were at higher risk for hypoglycaemia. The rate of 
hypoglycaemia was adjusted using the hazard ratio for hypoglycaemia for peripheral neuropathy 
versus no peripheral neuropathy [11]. Thus, patient populations with more advanced disease (and 
a higher prevalence of peripheral neuropathy) were at a higher risk for hypoglycaemia. 
Microalbuminuria and End-Stage Renal Disease 
Probabilities of microalbuminuria were derived from a Weibull function fitted to data 
from the DCCT and EDIC studies (Table 1 [12]). Conditional probabilities for end-stage renal 
disease in people with microalbuminuria [13] and for death in people with end-stage renal 
disease were based on published literature. 
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Proliferative Diabetic Retinopathy and Blindness 
Probabilities of proliferative diabetic retinopathy were derived from a Weibull function 
fitted to data from the DCCT and EDIC studies [5]. The annual probability of blindness (defined 
as severe vision loss, < 5/200) in people with proliferative diabetic retinopathy was estimated 
from the Early Treatment Diabetic Retinopathy Study trial. 
Diabetic Ketoacidosis 
The rate per patient-year was estimated from a linear function describing the change in 
the rate of diabetic ketoacidosis with age, fitted to data from the DCCT and EDIC studies [5]. 
Although poor glycaemic control and compliance have been reported to increase the risk of 
hospital admission for recurrent diabetic ketoacidosis [14], no hazard ratio estimates were 
identified for the association between ketoacidosis and HbA1c. The model allowed the user to 
enter a hazard ratio for HbA1c in order to explore the impact of a possible association. The 
probability of death from diabetic ketoacidosis was based on a published study. 
Pregnancy Outcomes 
The number of pregnancies during the model time horizon was estimated from UK 
general population birth rates. Probabilities of stillbirth, perinatal mortality, and congenital 
malformation were applied to estimate the number of cases of infant death and congenital 
malformation. Probabilities were adjusted for HbA1c using a published hazard ratio [15]. 
Infant deaths, life-years, and QALYs lost were estimated from the average life 
expectancy at birth for the UK population and an average lifetime utility weight. For infants with 
congenital malformation, life-years and QALYs lost were estimated using the difference in life 
expectancy and utility between infants with congenital malformation and infants in the general 
population. 
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[TABLE 1 HERE] 
Hypoglycaemia 
Hypoglycaemia was modelled as four separate events—non-severe day, non-severe 
nocturnal, severe day, and severe nocturnal—and were driven by user-entered data (e.g., 
observations from pivotal trials). No adjustment to the risk of hypoglycaemia was made for 
differences in HbA1c because any differences between interventions in the incidence of 
hypoglycaemia are expected to be observed during the trial (and the trial data would reflect any 
impact of differences in HbA1c levels between the two groups on the incidence of 
hypoglycaemia). 
No data were identified for the probability of death from individual severe 
hypoglycaemia events. The probabilities were calibrated so that the model result for the 
proportion of all deaths that were due to hypoglycaemia was consistent with published data [18]. 
Death From Other Causes 
Death from other causes was modelled using standard age- and sex-specific mortality 
rates for the UK general population. 
Valuation of Health Effects 
Default utility weights were based on the CORE diabetes model (Table S4). For people 
with multiple complications, the lowest utility weight of all chronic complications was applied to 
that year. Utility decrements for acute events were subtracted from the QALYs accrued during 
the year. 
 11 
Resource Utilisation and Costs 
Direct costs to the health care provider included interventions (drug acquisition, needles, 
and other costs) and management of Type 1 DM complications (based on published data; see 
Table S4). No estimates of indirect costs were available. The cost-year for the analysis was 2010. 
Sensitivity Analysis 
To account for uncertainty, the model was programmed to allow for univariate and 
probabilistic sensitivity analyses for all parameters. Distributions for the probabilistic sensitivity 
analyses were individually selected as appropriate for the underlying distribution of the data [19]. 
All variables were assumed to vary independently of one another. 
Validation 
Model validation was performed in alignment with best practice guidelines [20] and other 
diabetes models (e.g., [21]). 
Face validity (first-order validation in the diabetes modelling literature [20]) was ensured 
by clinical and economics experts’ (MD and AB) review of the model structure, data inputs, 
assumptions, and results. Internal validity was ensured by verification of all input parameters 
with original sources, checking of model formulae by an independent health economist, scenario 
testing, and verification of model results against independent calculations. 
Dependent external validation (second-order validation in the diabetes literature) was 
performed by comparing model predictions with outcomes observed in the studies used to build 
the model (the intensive-treatment groups from the DCCT and EDIC studies). Comparison with 
the conventional-treatment groups also was performed after adjustment of the population 
characteristics (HbA1c, age, duration of diabetes) and a further adjustment for the residual effect 
of treatment observed in the studies after adjusting for HbA1c. 
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Independent external validation (third-order validation in the diabetes modelling 
literature) was conducted by comparing model predictions with outcomes observed in studies 
that were not used to build the model. Studies identified by the systematic review were selected 
in which long-term cumulative incidence for a complication using similar endpoint definitions to 
the DCCT and EDIC studies were reported for a large cohort of people with T1DM and where 
sufficient baseline characteristics were reported to allow predictions for that population to be 
estimated within the model. 
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RESULTS 
Model Validation 
Model predictions were within 2% of expected values in the dependent external (second 
order) validation and within 8% of values reported from other studies in the independent external 
(third-order) validation (Table 2 and Table 3, Fig. 2, Fig. 3) (percentages represent absolute 
differences in the cumulative incidence). 
[TABLE 2, TABLE 3 [22-29 NEW], FIG. 2, FIG. 3 HERE] 
Model Predictions for Example Patient Cohorts 
Table 4 presents model predictions for the general Type 1 DM population in the UK and 
for subpopulations of men, women (including and excluding adverse pregnancy outcomes), and 
people with specific ages and durations of diabetes. 
[TABLE 4 HERE] 
Cost-Utility Analysis Results for a Hypothetical Intervention 
An analysis was performed for a hypothetical intervention with an annual drug cost of 
£700 (vs. £600 for the control drug). The mean change in HbA1c from baseline was 
12 mmol/mol (1.1%) for the intervention and 11 mmol/mol (1.0%) for the control. The analysis 
was conducted over a timeframe of 50 years for a Type 1 DM population in the UK with the 
following characteristics: mean age, 39 years; mean disease duration, 11 years; mean HbA1c, 
72 mmol/mol (8.7%); and 43% women (adverse pregnancy outcomes were excluded). The 
number of first-order simulations required for this analysis was investigated at intervals between 
1,000 and 100,000 simulations (Table S5). In simulation models, a standard error of less than 5% 
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of the mean is typically considered acceptable [30]. This was achieved with 50,000 first-order 
simulations. 
Fig. 4 presents the cumulative incidence of complications for the intervention and control 
cohorts. As expected, the cumulative incidence of events was slightly lower for the intervention 
cohort (solid lines) than for with the control cohort (dotted lines). Table 5 presents the results for 
a hypothetical intervention. Cost-offsets due to reduced complications outweighed the increased 
drug costs, resulting in lower overall costs for the cohort receiving the intervention of interest. 
The intervention therefore was dominant. An analysis was performed to estimate the maximum 
value-based price for the intervention at a willingness-to-pay threshold of £20,000 per QALY. 
The maximum annual cost of the intervention was £460 higher than that of the control drug. The 
results of a probabilistic sensitivity analysis for 1,000 second-order and 50,000 first-order 
simulations are presented in Fig. S1 and Fig. S2, respectively. 
[TABLE 5 HERE; FIG. 4 HERE] 
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DISCUSSION 
To our knowledge, this is the first cost-effectiveness model developed specifically for 
Type 1 DM using up-to-date, systematically identified evidence. Only complications for which 
improved glycaemic control has been demonstrated to reduce the risk were modelled. A 
comprehensive model validation process was undertaken; in the dependent and independent 
external validation, model predictions were within 2% and 8% of expected values, respectively. 
This compares well with validation results from other diabetes models [21]. In analyses of the 
example patient cohorts, model predictions were consistent with expected results. 
Several simplifying assumptions were made due to limitations in the available data and to 
meet the objective to develop a simple and accessible model. Assumptions included simplifying 
the interactions between complications and applying the lowest utility weight of all 
complications in people with more than one complication. The latter approach is consistent with 
other diabetes models (e.g., the CORE model [21]); however, this approach may underestimate 
QALY losses if the presence of multiple complications results in greater impairment than does 
the worst of the complications alone. It is possible that simplification of interactions between 
complications may result in a wider distribution of complications among the population. For 
simplicity and due to paucity of available data, the risk of complications worsening or recurring 
was not adjusted for the HbA1c level. For example, the risk of a first cardiovascular event was 
adjusted for HbA1c, but the risk of subsequent events was not. 
A number of Type 1 DM complications (e.g., anxiety, depression, autoimmune 
thyroiditis, and limited joint mobility) were excluded from the model (Table S2). It is possible 
that these complications are influenced by HbA1c levels, but research demonstrating such an 
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association has been insufficient. If improved glycaemic control does reduce the incidence of 
these complications, the model may underestimate the benefit of improved control and therefore 
may be conservative when considering the benefit of interventions associated with improved 
glycaemic control. 
A limitation of the model is that reduction in HbA1c levels may not reflect the full 
benefit of more effective glycaemic control. In the DCCT, HbA1c accounted for approximately 
90% of the treatment effect, but there was a residual treatment effect that was not explained by 
HbA1c [1]. In addition, the model does not explicitly incorporate the costs and effects of 
treatments that are used to prevent cardiovascular complications (e.g., statins and 
antihypertensive agents). 
The prediction of long-term outcomes and the effect of HbA1c, age, and disease duration 
is subject to uncertainty. The risk of death from hypoglycaemia was difficult to estimate. This is 
likely to be an important driver of cost-effectiveness estimates when the incidence of severe 
hypoglycaemia differs among treatments. 
In our model, the treatment effects can be user defined. Therefore, it is not possible to 
provide firm guidelines regarding the number of individual people that should be simulated in 
order to achieve reproducible results. This should be determined by the user for individual 
analyses, as demonstrated in the example analysis for a hypothetical intervention. Run times for 
the probabilistic sensitivity analysis will vary from less than an hour to many hours, depending 
on the number of first-order (individual patient) simulations and second-order (probabilistic) 
simulations required and the speed of the computer processor. Whilst Excel is not the optimum 
software with respect to speed, it was selected in order to provide the required transparency and 
accessibility for multiple users. 
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In conclusion, we have developed a simple, probabilistic individual patient-simulation 
model based on recent data specific to Type 1 DM (where available) that included only those 
complications for which improved glycaemic control has been demonstrated to reduce the risk. 
In external validations, model predictions varied by less than 8% from expected values. 
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TABLES 
Table 1. Risk Functions for Type 1 DM Complications 
 
Source Function γ α 
Hazard Ratio: 
HbA1c 
Hazard Ratio: 
Age 
Hazard Ratio: 
Duration of 
Diabetes 
CVDa DCCT/EDIC 
Nathan et al. 
[1] 
Weibull  0.4574 4.3074 1.25 
(1.10-1.43) 
1.06 
(1.04-1.08)b 
NAa 
Cataract 
surgery 
Grauslund et 
al. [8] 
Weibull 0.9648 3.6095 1.22 
(0.91-1.64) 
Nonec 1.16 
(0.88-1.53) 
Peripheral 
neuropathyd 
DCCT/EDIC 
Albers et al. 
[10] 
Weibull 0.7123 3.3370 1.53 
(0.99-2.37) 
NAd 1.06 
(1.01-1.11) 
Micro-
albuminuriae 
DCCT/EDIC 
de Boer et al. 
[12] 
Partitioned 
(Weibull + log-
logistic)e 
Weibull: 
0.4238 
Log-logistic: 
Weibull: 
2.6727 
Log-logistic: 
1.80 
(1.54-2.10) 
1.03 
(1.00-1.07) 
Noneg 
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Source Function γ α 
Hazard Ratio: 
HbA1c 
Hazard Ratio: 
Age 
Hazard Ratio: 
Duration of 
Diabetes 
0.0048f 0.9919f 
Proliferative 
diabetic 
retinopathyh 
DCCT/EDIC 
Nathan et al. 
[5] 
Weibull 0.3184 3.8612 1.38 
(1.31-1.46) 
Noneh Noneg 
CVD = cardiovascular disease; DCCT = Diabetes Control and Complications Trial; EDIC = Epidemiology of Diabetes Interventions and 
Complications study; FinnDiane = Finnish Diabetic Nephropathy study; HbA1c = glycated haemoglobin; NA = not applicable; Type 1 DM = Type 1 
diabetes mellitus. 
a The function described the cumulative incidence of CVD with time and was adjusted for HbA1c and age. Statistical models did not include 
duration of diabetes due to colinearity with age (e.g., [16]). Adjustment for diabetes duration was performed by selecting the appropriate start point 
on a curve based on the baseline diabetes duration of the model population. 
b Gordin et al. [16] (FinnDiane) (not available from DCCT or EDIC). 
c Adjustment of the function for age was not appropriate because the function described the cumulative incidence with age. 
d The function described the cumulative incidence of peripheral neuropathy with time and was adjusted for HbA1c and diabetes duration. 
Statistical models did not include age due to colinearity with diabetes duration. Adjustment for age was performed by selecting the appropriate 
start point on curve based on the baseline age of the model population. 
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e The function described the cumulative incidence of microalbuminuria with increasing disease duration and was adjusted for HbA1c and age. A 
partitioned function was used in which the risk of a proportion of was described by a Weibull function and the risk to the remaining patients was 
described by a log-logistic function. The proportion of patients governed by the log-logistic function (86%) was estimated as a parameter during 
the fitting of the partitioned function. 
f Log-logistic location parameter. 
g Adjustment for duration was not appropriate because the function described the cumulative incidence with duration of diabetes. 
h The function described the cumulative incidence of proliferative diabetic retinopathy with duration of diabetes and was adjusted for HbA1c. The 
function was not adjusted for age because many studies found no independent association between age and retinopathy after adjustment for 
duration of diabetes (e.g., De Block et al. [17]). 
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Table 2. Internal Validation Results 
Complication Study 
Study Estimate for 
Cumulative Incidence or 
Validation Study Details 
Validation Estimate for 
Cumulative Incidence or 
Model Estimate for 
Cumulative Incidence 
Difference/ 
Comments 
CVD DCCT and EDIC 
Nathan et al. [1] (Fig. 1, 
intensive-treatment group) 
2.9% 2.6% –0.3% 
Microalbumin-
uria 
DCCT and EDIC 
de Boer et al. [12] (Fig. 1, 
intensive-treatment 
group)a 
21.0% 20.6% –0.4% 
Proliferative 
diabetic 
retinopathy 
DCCT and EDIC 
Nathan et al. [5] (Fig. 2A, 
intensive-treatment 
group)b 
7.8% 6.3% –1.5% 
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Complication Study 
Study Estimate for 
Cumulative Incidence or 
Validation Study Details 
Validation Estimate for 
Cumulative Incidence or 
Model Estimate for 
Cumulative Incidence 
Difference/ 
Comments 
Cataract 
surgery 
Grauslund et al. [8] (Fig. 2, 
Type 1 diabetes mellitus 
group)c 
0.0% 0.0% 0.0% 
Peripheral 
neuropathy 
EDIC 
Martin et al. [22] (Fig. 1, 
intensive-treatment 
group)d 
33.9% 33.2% –0.7% 
CVD = cardiovascular disease; DCCT = Diabetes Control and Complications Trial; EDIC = Epidemiology of Diabetes Interventions and 
Complications study. 
a Incidence for a duration of diabetes of 21 years (6 years at model entry + 15 years in model). Estimate was approximate as it was taken from a 
Kaplan-Meier curve with large steps at this point. 
b Incidence for a duration of diabetes of 21 years (6 years at model entry + 15 years in model). 
c Age at 15 years = 42; incidence of cataract surgery before age 50 = 0 [8]. 
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d Approximate data. The incidence in the DCCT and the EDIC study at baseline was 7%; at 13.5 years, incidence was 25% [10]. The derived 
Weibull function for the intensive-treatment group predicted a cumulative incidence of 26.9% at 15 years (incidence at baseline = 0). Estimated 
incidence at 15 years therefore was 26.9% + 7% = 33.9%. 
 32 
Table 3. External Validation Results 
Complication Study 
Study Estimate for 
Cumulative Incidence or 
Validation Study Details 
Validation Estimate for 
Cumulative Incidence or 
Model Estimate for 
Cumulative Incidence 
Difference/ 
Comments 
Cardiovascular 
disease 
Cumulative incidence, 
hazard ratio, HbA1c: 
DCCT and EDIC, Nathan 
et al. [1] 
Cardiovascular disease 
included myocardial 
infarction,a stroke, angina,b 
revascularisation,c and 
cardiovascular death 
Hazard ratio, age and 
duration: EURODIAB, 
Soedamah-Muthu et al. 
EDC, Conway et al. [24] 
Coronary artery disease 
included myocardial 
infarction,d 
revascularisation,e 
stenosis,f and fatal 
coronary artery disease 
Patients diagnosed 1950-
1980; enrolled in EDC 
1986-1988 
26% at 
20 years of 
follow-upg 
Risk 
equation: 
21% at 20 
years of 
follow-up 
Model adjusted for 
difference in HbA1c 
between population 
underpinning model data 
(DCCT intensive 
treatment) and EDC, but 
other effects of 
contemporary 
management may account 
for the higher incidence in 
EDC 
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Complication Study 
Study Estimate for 
Cumulative Incidence or 
Validation Study Details 
Validation Estimate for 
Cumulative Incidence or 
Model Estimate for 
Cumulative Incidence 
Difference/ 
Comments 
[23] 
Coronary heart disease 
included clinical 
myocardial infarction, 
angina, coronary artery 
bypass graft surgery, 
electrocardiogram 
abnormality 
Cataract 
surgery 
Confidence interval: 
Grauslund et al. [8] 
None Not 
applicable 
Not 
applicable 
External validation was not 
possible because no 
studies were identified that 
reported cumulative 
incidence of cataract 
surgery in patients with 
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Complication Study 
Study Estimate for 
Cumulative Incidence or 
Validation Study Details 
Validation Estimate for 
Cumulative Incidence or 
Model Estimate for 
Cumulative Incidence 
Difference/ 
Comments 
Type 1 DM other than 
Grauslund et al. [8] 
Peripheral 
neuropathy 
Confidence interval: DCCT 
and EDIC, Albers et al. 
[10] 
Confirmed clinical 
neuropathy based on 
neurologist’s examinationh 
Hazard ratio, HbA1c: 
Nordic registry, Bragd et 
al. [25] 
Sensory neuropathy, as 
indicated by pathological 
thresholds revealed by 
EURODIAB, Tesfaye et al. 
[26,27] 
Abnormalities in at least 2 
of 4 assessmentsi 
Baseline examinations 
were conducted between 
1989 and 1991 
Patients with no peripheral 
neuropathy at baseline 
were followed up 
Mean duration of diabetes: 
14.7 ± 9.3 years 
23.5% at 
7.3 years of 
follow-up 
Risk 
equation: 
22.2% at 
7.3 years of 
follow-up 
Model estimate was close 
to and lower than 
observed in EURODIAB 
The EURODIAB studied 
patients who were 
diagnosed relatively 
recently 
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Complication Study 
Study Estimate for 
Cumulative Incidence or 
Validation Study Details 
Validation Estimate for 
Cumulative Incidence or 
Model Estimate for 
Cumulative Incidence 
Difference/ 
Comments 
neurometry and/or a 
vibration test with tuning 
fork and monofilament 
testing 
Microalbumin-
uria 
DCCT and EDIC, de Boer 
et al. [12] 
Persistent 
microalbuminuria, albumin 
excretion rate of at least 
30 mg per 24 hours at 2 
consecutive study visits 
Giordano et al. [28] 
Microalbuminuria, albumin 
levels of 30-300 mg in a 
24-hour urine collection 
23.0% at 
10 years 
from 
diagnosisj 
28.5% at 10 
years from 
diagnosis 
Giordano cohort consisted 
of 336 of 1,118 treatment-
naïve Sicilian patients 
hospitalised for Type 1 DM 
in 1991-2005 
Definition of 
microalbuminuria in 
Giordano study was less 
stringent (albumin 
excretion rate e 30 mg in 1 
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Complication Study 
Study Estimate for 
Cumulative Incidence or 
Validation Study Details 
Validation Estimate for 
Cumulative Incidence or 
Model Estimate for 
Cumulative Incidence 
Difference/ 
Comments 
sample rather than 2 
consecutive samples) 
Proliferative 
diabetic 
retinopathy 
DCCT and EDIC, Nathan 
et al. [5] 
Proliferative diabetic 
retinopathy or worse, 
ETDRS grading scale, and 
DCCT methods 
FinnDiane, Hietala et al. 
[29] 
ETDRS grading scale 
23.0% at 
20 years 
and 46.0% 
at 30 years 
from 
diagnosisk 
16.5% at 20 
years and 
47.7% at 30 
years from 
diagnosis 
Model estimate was lower 
at 20 years and  higher at 
30 years 
All-cause 
mortality 
Multiple data sources used 
for death from individual 
Type 1 DM complications 
and other causes 
Finne et al. [13] 
20,005 patients younger 
than 30 years diagnosed 
with Type 1 DM in Finland 
between 1965 and 1999, 
identified from the Finnish 
15% 18.9% Model estimate was higher 
than that observed by 
Finne et al. [13] 
Assumptions about 
baseline characteristics 
(as these were not 
 37 
Complication Study 
Study Estimate for 
Cumulative Incidence or 
Validation Study Details 
Validation Estimate for 
Cumulative Incidence or 
Model Estimate for 
Cumulative Incidence 
Difference/ 
Comments 
Diabetes Register 
Baseline characteristics 
were not fully reported, so 
assumptions were applied 
during the validation 
reported by Finne et al. 
[13]) may have introduced 
error 
DCCT = Diabetes Control and Complications Trial; EDC = Epidemiology of Diabetes Complications study; EDIC = Epidemiology of Diabetes 
Interventions and Complications study; ETDRS = Early Treatment Diabetic Retinopathy Study; EURODIAB = Epidemiology and Prevention of 
Diabetes in Europe study; FinnDiane = Finnish Diabetic Nephropathy study; HbA1c = glycated haemoglobin; Type 1 DM = Type 1 diabetes 
mellitus. 
a Clinical and subclinical (silent) myocardial infarction (identified on the annual electrocardiograms). 
b Confirmed by ischaemic changes on exercise tolerance testing or by clinically significant obstruction on coronary angiography. 
c With angioplasty or coronary artery bypass graft. 
d Confirmed on medical records or Q-waves (Minnesota code 1.1 or 1.2). 
e Including coronary artery bypass graft, angioplasty, and coronary endarterectomy. 
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f Coronary artery stenosis e 50% without revascularisation. 
g Estimated from Conway et al. [24], Fig. 1 (top left). 
h Required at least 2 positive responses among symptoms, sensory signs, or reflex changes consistent with a distal symmetrical polyneuropathy 
(e.g., symptoms or signs showing a length-dependent gradient in a stocking or stocking-glove distribution) and nerve conduction study 
abnormalities involving 2 or more nerves among the median, peroneal, and sural nerves. 
i The assessment of neuropathy included (1) evaluation of neuropathic symptoms, (2) scored clinical examination, (3) measurement of vibration 
perception threshold, and (4) autonomic function tests by measuring 2 cardiovascular reflex responses. The criterion for the presence of diabetic 
peripheral neuropathy was if abnormalities were found in 2 or more of these 4 assessments. 
j Estimated from Giordano et al. [28], Fig. 3A. 
k Estimated from Hietala et al. [29], Fig. 1. 
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Table 4. Model Predictions for Example Population Cohorts (Mean Total Expected 
Lifetime Values; 50,000 Iterations; Costs and Outcomes Discounted at 3.5%) 
Population Total Cost Total LYs Total QALYs 
UK Type 1 DM Populationa £148,600 17.62 5.77 
Males £147,808 17.64 5.79 
Females (including pregnancy 
outcomes) 
£148,547 17.41 5.20 
Females (excluding pregnancy 
outcomes) 
£148,547 17.70 5.81 
Aged 25 yearsb £170,151 20.90 6.96 
Aged 30 yearsb £164,997 20.11 6.68 
Aged 35 yearsb £156,828 18.86 6.24 
Diabetes duration of 5.5 yearsc £128,167 18.46 6.80 
Diabetes duration of 15 yearsc  £162,367 17.13 5.13 
Diabetes duration of 20 yearsc  £180,580 16.55 4.31 
HbA1c = glycated haemoglobin; LY = life-year; QALY = quality-adjusted life-year; Type 1 DM = Type 1 
diabetes mellitus; UK = United Kingdom. 
a Age = 39 years; duration of diabetes = 11 years; HbA1c level = 72 mmol/mol (8.7%); gender (% 
female) = 43%; angina = 4%; prior myocardial infarction = 1.5%; prior revascularisation = 0.0%; disabled 
from stroke = 1.0%; cataract, partially sighted = 1.0%; peripheral neuropathy = 6.8%; active foot 
ulcer = 0.0%; amputee = 0.5%; microalbuminuria = 1.0%; end-stage renal disease = 1.5%; proliferative 
diabetic retinopathy = 3.5%; proliferative diabetic retinopathy blind = 1.0%. Adverse pregnancy outcomes 
not included. 
b Diabetes duration set at default: 11 years. 
c Age set at default: 39 years. 
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Table 5. Cost-Utility Analysis Results for a Hypothetical Intervention (Costs and 
Outcomes Discounted at 3.5%) 
Model Set-Up Intervention Control 
Annual drug cost £700 £600 
Annual other treatment cost £100 £100 
Mean change in HbA1c 
(standard error) 
–12 mmol/mol [1.1%] 
(1 mmol/mol [0.1%]) 
–11 mmol/mol [1.0%] 
(1 mmol/mol [0.1%]) 
Severity Rate Ratio Hypoglycaemiaa (Standard Error) 
Non-severe (day) 1.00 (0.05) 
Non-severe (nocturnal) 0.90 (0.05) 
Severe (day and nocturnal) 0.95 (0.05) 
Results Intervention Control Incremental Cost 
Drug £10,674 £8,872 £1,801 
Other treatment cost £1,779 £1,774 £5 
Complications £133,191 £136,759 –£3,568 
Total cost (95% CI) £145,644 (116,468, 
326,076) 
£147,406 (117,151, 
178,109) 
–£1,762 (–13,451, 
8,629) 
Life-years (95% CI) 17.70 (16.72, 18.50) 17.64 (16.71, 18.42) 0.05 (–0.11, 0.19) 
QALYs (95% CI) 6.02 (3.82, 7.57) 5.79 (3.72, 7.33) 0.23 (–0.30, 0.73) 
Incremental cost per 
QALY 
Intervention dominant; probability of cost-effectiveness: 0.72b 
CI = confidence interval; HbA1c = glycated haemoglobin; QALY = quality-adjusted life-year. 
a Rate ratio for intervention versus control. 
b Probability of cost-effectiveness at a willingness-to-pay threshold of £20,000 per QALY. 
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FIGURE LEGENDS 
Figure 1. Diagrammatic Representation of the Individual Patient-Simulation Model 
AMP = amputation; CS = cataract surgery; CVD = cardiovascular disease; DKA = diabetic ketoacidosis; 
ESRD = end-stage renal disease; FU = foot ulcer; HbA1c = glycated haemoglobin; 
hypo = hypoglycaemia; ICM = infant congenial malformation; ID = infant death; MA = microalbuminuria; 
MI = myocardial infarction; PDR = proliferative diabetic retinopathy; PN = peripheral neuropathy; 
REVASC = revascularisation; Type 1 DM = Type 1 diabetes mellitus. 
Note: All-cause mortality was included in the model; people with any complications or none could die of 
other causes. 
a The data used to estimate the parametric function for CVD represented the time to the first of any 
predefined CVD event (non-fatal acute MI, silent MI, stroke, death from CVD, confirmed angina, or the 
need for coronary artery revascularisation). Patients with silent MI were assumed to have no CVD. 
b Separate costs and utilities were applied for the first year (in which the event occurred) and for 
subsequent years. Patients can become permanently disabled or can recover. For patients without 
permanent disability, no cost or utility impact were applied after recovery. 
c Patients are assumed to have substantially impaired vision due to cataract for the year before the 
cataract surgery. The probability of a second surgery was assumed independent of previous cataract 
surgery. 
d FUs can become infected and patients could develop gangrene. 
e Patients can have up to 2 amputations. 
f Hypoglycaemic events were modelled separately as follows: non-severe day, non-severe nocturnal, 
severe day, and severe nocturnal. Specific mortality was for severe events only. 
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g Data from this outcome can be included or excluded from the results of individual analyses. Fixed 
probabilities were adjusted using the hazard ratio for HbA1c. 
Figure 2. Dependent External (Second-Order) Validation: Comparison With the 
DCCT and EDIC Conventional-Treatment Group (IA Through IVA) and 
Independent External (Third-Order) Validation: (IB Through IVB) 
CT = conventional treatment; DCCT = Diabetes Control and Complications Trial; EDC = Epidemiology of 
Diabetes Complications study; EDIC = Epidemiology of Diabetes Interventions and Complications study; 
EURODIAB = Epidemiology and Prevention of Diabetes in Europe study; FinnDiane = Finnish Diabetic 
Nephropathy study; IT = intensive treatment. 
Sources: Fig. IB, the EDC Study, Conway et al. [24]; Fig. IIB, the EURODIAB Study, Tresfaye et al. [26]; 
Fig. IIIB, Giordano et al. [28]; Fig. IVB, the FinnDiane Study, Hietala et al. [29]. 
Figure 3. Graphical Presentation of the Results of the Dependent External 
(Second-Order) and Independent External (Third-Order) Validation of the Model 
CT = conventional treatment; DCCT = Diabetes Control and Complications Trial; IT = intensive treatment. 
Note: Model estimates are plotted against data reported in the external validation studies (original data). 
The straight line represents equivalence between the model estimates and the original data. 
Figure 4. Cumulative Incidence of Complications for a Hypothetical Intervention 
and Control 
CVD = cardiovascular disease; MA = microalbuminuria; PDR = proliferative diabetic retinopathy; 
PN = peripheral neuropathy. 
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FIGURES 
Figure 1. Diagrammatic Representation of the Individual Patient-Simulation Model 
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AMP = amputation; CS = cataract surgery; CVD = cardiovascular disease; DKA = diabetic ketoacidosis; ESRD = end-stage renal disease; 
FU = foot ulcer; HbA1c = glycated haemoglobin; hypo = hypoglycaemia; ICM = infant congenial malformation; ID = infant death; 
MA = microalbuminuria; MI = myocardial infarction; PDR = proliferative diabetic retinopathy; PN = peripheral neuropathy; 
REVASC = revascularisation; Type 1 DM = Type 1 diabetes mellitus. 
Note: All-cause mortality was included in the model; people with any complications or none could die of other causes. 
a The data used to estimate the parametric function for CVD represented the time to the first of any predefined CVD event (non-fatal acute MI, 
silent MI, stroke, death from CVD, confirmed angina, or the need for coronary artery revascularisation). Patients with silent MI were assumed to 
have no CVD. 
b Separate costs and utilities were applied for the first year (in which the event occurred) and for subsequent years. Patients can become 
permanently disabled or can recover. For patients without permanent disability, no cost or utility impact were applied after recovery. 
c Patients are assumed to have substantially impaired vision due to cataract for the year before the cataract surgery. The probability of a second 
surgery was assumed independent of previous cataract surgery. 
d FUs can become infected and patients could develop gangrene. 
e Patients can have up to 2 amputations. 
f Hypoglycaemic events were modelled separately as follows: non-severe day, non-severe nocturnal, severe day, and severe nocturnal. Specific 
mortality was for severe events only. 
 45 
g Data from this outcome can be included or excluded from the results of individual analyses. Fixed probabilities were adjusted using the hazard 
ratio for HbA1c. 
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Figure 2. Dependent External (Second-Order) Validation: Comparison With the 
DCCT and EDIC Conventional-Treatment Group (IA Through IVA) and 
Independent External (Third-Order) Validation: (IB Through IVB) 
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CT = conventional treatment; DCCT = Diabetes Control and Complications Trial; EDC = Epidemiology of 
Diabetes Complications study; EDIC = Epidemiology of Diabetes Interventions and Complications study; 
EURODIAB = Epidemiology and Prevention of Diabetes in Europe study; FinnDiane = Finnish Diabetic 
Nephropathy study; IT = intensive treatment. 
Sources: Fig. IB, the EDC Study, Conway et al. [24]; Fig. IIB, the EURODIAB Study, Tresfaye et al. [26]; 
Fig. IIIB, Giordano et al. [28]; Fig. IVB, the FinnDiane Study, Hietala et al. [29]. 
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Figure 3. Graphical Presentation of the Results of the Dependent External 
(Second-Order) and Independent External (Third-Order) Validation of the Model 
 
CT = conventional treatment; DCCT = Diabetes Control and Complications Trial; IT = intensive treatment. 
Note: Model estimates are plotted against data reported in the external validation studies (original data). 
The straight line represents equivalence between the model estimates and the original data. 
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Figure 4. Cumulative Incidence of Complications for a Hypothetical Intervention 
and Control 
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CVD = cardiovascular disease; MA = microalbuminuria; PDR = proliferative diabetic retinopathy; 
PN = peripheral neuropathy. 
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SUPPORTING INFORMATION  
DEVELOPMENT AND VALIDATION OF A COST-UTILITY MODEL 
FOR TYPE 1 DIABETES MELLITUS 
S. Wolowacz, I. Pearson, P. Shannon, B. Chubb, J. Gundgaard, M. Davies and 
A. Briggs 
Definition of Type 1 Diabetes Mellitus 
The World Health Organization defines Type 1 diabetes mellitus (DM) as a 
condition of deficiency of insulin secretion from the pancreas, usually due to auto-
immune damage of the insulin-producing cells. However, the clinical condition 
generally is recognised on the basis of diabetes (high blood glucose levels) 
occurring in mainly younger and thinner people in the absence of other precipitating 
causes (WHO, 1999). 
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Mathieu C, et al. Development and validation of the Economic Assessment of 
Glycemic Control and Long-Term Effects of diabetes (EAGLE) model. Diabetes 
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 Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, et al. The 
CORE Diabetes Model: projecting long-term clinical outcomes, costs and 
cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to 
support clinical and reimbursement decision making. Curr Med Res Opin 
2004; 20(suppl 1): S5-26. 
 Eddy DM, Schlessinger L. Archimedes: a trial-validated model of diabetes. 
Diabetes Care 2003; 26: 3093-1. 
 Mount Hood 4 Modeling Group. Computer modeling of diabetes and its 
complications, a report on the Fourth Mount Hood Challenge Meeting. 
Diabetes Care 2007; 30: 1638-46. 
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Table S1. Default Model Population Characteristics at Entry 
Characteristica Value Source 
Mean age, in years 39 Lauterbach et al., 2010 
Mean duration of diabetes, in years 11 Lauterbach et al., 2010 
Mean HbA1c, in mmol/mol (%) 72 (8.7) Lauterbach et al., 2010 
Sex (% female) 43 Lauterbach et al., 2010 
Angina (%) 4.0 United Kingdom National 
Diabetes Audit, 2010b 
Prior myocardial infarction (%) 1.5 United Kingdom National 
Diabetes Audit, 2010b 
Prior revascularisation (%) 0.0 Assumption 
Disabled from stroke (%) 1.0 United Kingdom National 
Diabetes Audit, 2010 
Cataract, partially sighted (%) 1.0 Assumption 
Peripheral neuropathy (%) 6.8 Lauterbach et al., 2010 
Active foot ulcer (%) 0.0 Assumption 
Amputee (%) 0.5 United Kingdom National 
Diabetes Audit, 2010 
Microalbuminuria (%) 1.0 Färnkvist and Lundman, 2003 
End-stage renal disease (%) 1.5 United Kingdom National 
Diabetes Audit, 2010 
Proliferative diabetic retinopathy (%) 3.5 United Kingdom National 
Diabetes Audit, 2010 
Proliferative diabetic retinopathy, blind (%) 1.0 Assumption 
HbA1c = glycosylated haemoglobin. 
a The model adjusted the probabilities of complications for patients’ age, duration of diabetes, and 
HbA1c; probabilities of death were dependent on age and sex. Probabilities of hypoglycaemia were 
adjusted for the presence of peripheral neuropathy. 
b Data for Type 1 diabetes mellitus estimated from the United Kingdom National Diabetes Audit, 2010, 
Figure 14, page 19. 
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Table S2. Selection of Type 1 Diabetes Mellitus Complications for Incorporation in the Economic Model 
Complication 
Associated With Type 1 
Diabetes Mellitus 
Associated with Glycaemic 
Control and/or HbA1c 
Selected 
(Yes/No) Reason for Exclusion 
Anxiety and 
depression 
Unclear; conflicting evidence, 
possibly confounded by 
comorbidities 
Unclear; association 
demonstrated but causality is 
questionable 
No Insufficient evidence that 
effective diabetes management 
reduces the risk of Type 1 
diabetes mellitus 
Autoimmune 
thyroiditis 
Yes; approximately 10% of 
patients require treatment; 
screening programmes are in 
place in some countries 
(Kordonouri et al., 2005; 
Mantovani et al., 2007) 
Unclear; not investigated No Insufficient evidence that 
effective diabetes management 
reduces the risk of Type 1 
diabetes mellitus; minor impact 
on costs and health-related 
quality of life 
Cardio-
vascular 
disease 
Yes; angina, hypertension, 
myocardial infarction, and 
stroke (Klein et al., 2004) 
Yes; the decrease in HbA1c 
values during DCCT was 
significantly associated with 
most of the positive effects of 
intensive treatment on the 
risk of cardiovascular disease 
(Nathan et al., 2005) 
Yes Not applicable 
Carpel tunnel 
syndrome 
Yes; predicted lifetime risk 
was approximately 85% after 
54 years of Type 1 diabetes 
mellitus (Singh et al., 2005) 
No; there was no 
demonstrable effect of 
glycaemic control on the 
incidence of carpel tunnel 
syndrome (Singh et al., 2005) 
No Insufficient evidence that 
effective diabetes management 
reduces the risk of Type 1 
diabetes mellitus; relatively 
minor impact on health-related 
quality of life 
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Complication 
Associated With Type 1 
Diabetes Mellitus 
Associated with Glycaemic 
Control and/or HbA1c 
Selected 
(Yes/No) Reason for Exclusion 
Cataract Yes; 25-year crude incidence 
of cataract surgery was 
approximately 20% 
(Grauslund et al., 2011) 
Yes; the hazard ratio for risk 
of cataract surgery was 1.22 
(95% confidence interval: 
0.91-1.64) [reported value 
inverted to give the hazard 
ratio for an 11-mmol/mol 
(1.0%) increase in HbA1c] 
(Grauslund et al., 2011) 
Yes Not applicable 
Cognitive 
dysfunction 
Unclear; conflicting evidence Unclear; association 
demonstrated but cause and 
effect not established 
No Insufficient evidence that 
effective diabetes management 
reduces the risk of Type 1 
diabetes mellitus 
Cutaneous 
manifestations 
Yes; there was a higher 
prevalence in patients with 
Type 1 diabetes mellitus than 
in control subjects (Pavlovic et 
al., 2007) 
No; there was no evidence to 
relate diabetic hand to 
metabolic control (Pavlovic et 
al., 2007) 
No Insufficient evidence that 
effective diabetes management 
reduces the risk of Type 1 
diabetes mellitus 
Female sexual 
dysfunction 
Unclear; conflicting evidence Unclear; conflicting evidence No Insufficient evidence that 
effective diabetes management 
reduces the risk of Type 1 
diabetes mellitus 
Male sexual 
dysfunction 
Unclear; only 1 study 
identified (Enzlin et al., 2003) 
Unclear; only 1 study 
identified (Enzlin et al., 2003) 
No Insufficient evidence that 
effective diabetes management 
reduces the risk of Type 1 
diabetes mellitus 
Fracture Unclear; conflicting evidence Unclear; no evaluation of the 
impact of HbA1c levels on 
fracture risk identified 
No Insufficient evidence that 
effective diabetes management 
reduces the risk of Type 1 
diabetes mellitus 
Hypogly-
caemia 
Yes; reported severe 
hypoglycaemia (coma or 
seizure) rates ranged from 
Yes; HbA1c was inversely 
related with rate of severe 
hypoglycaemia with an effect 
Yes Not applicable 
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Complication 
Associated With Type 1 
Diabetes Mellitus 
Associated with Glycaemic 
Control and/or HbA1c 
Selected 
(Yes/No) Reason for Exclusion 
5.4% to 19.0% per 100 
patient-years in the EDIC, 
DCCT, and EDC Type 1 
diabetes mellitus populations 
(Nathan et al., 2009) 
corresponding to a relative 
risk of 1.4% in the lowest 
HbA1c quartile, compared with 
the upper quartile (Pedersen-
Bjergaard et al., 2004) 
Ketoacidosis Yes; rate of ketoacidosis 
events reported in DCCT, 
EDIC, and EDC ranged from 
0% to 3.1% per 100 patient-
years (Nathan et al., 2009) 
Yes; HbA1c was a significant 
predictor of ketoacidosis 
(P = 0.001) (Craig et al., 
2007) 
Yes Not applicable 
Limited joint 
mobility 
Unclear; limited evidence, 
only 1 study identified 
(Lindsay et al., 2005) 
Unclear; limited evidence, 
only 1 study identified 
(Lindsay et al., 2005) 
No Insufficient evidence that 
effective diabetes management 
reduces the risk of Type 1 
diabetes mellitus 
Myopia Unclear; limited evidence, 
only 1 study identified 
(Jacobsen et al., 2008) 
Unclear; limited evidence, 
only 1 study identified 
(Jacobsen et al., 2008) 
No Insufficient evidence that 
effective diabetes management 
reduces the risk of Type 1 
diabetes mellitus 
Non-alcoholic 
fatty liver 
disease 
Unclear; limited evidence, 
only 1 study identified 
(Targher et al., 2010) 
Unclear; limited evidence, 
only 1 study identified 
(Targher et al., 2010) 
No Insufficient evidence that 
effective diabetes management 
reduces the risk of Type 1 
diabetes mellitus 
Peripheral 
neuropathy, 
foot ulcer, and 
amputation 
Yes; incidence rate for lower-
extremity amputation was 
3.2% (95% confidence 
interval: 1.2-9.4) per 1,000 
patients with Type 1 diabetes 
mellitus (McAlpine et al., 
2005) 
Yes; higher HbA1c (per 11-
mmol/mol (1.0%) odds ratio: 
1.40; 95% confidence 
interval: 1.24-1.58) was 
independently associated with 
the incidence of lower-
extremity amputation 
(Sahakyan et al., 2011) 
Yes Not applicable 
Pregnancy, 
birth outcomes 
Yes; the congenital 
malformation rates was 5.0% 
Yes; for HbA1c levels 
> 53 mmol/mol (7.0%), there 
Yes Not applicable 
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Complication 
Associated With Type 1 
Diabetes Mellitus 
Associated with Glycaemic 
Control and/or HbA1c 
Selected 
(Yes/No) Reason for Exclusion 
in the Type 1 diabetes 
mellitus population and 2.8% 
(relative risk: 1.7; 95% 
confidence interval: 1.3-2.2) 
in the background population 
(Jensen et al., 2004) 
was an almost linear 
association between HbA1c 
and risk of adverse outcome, 
whereby an 11-mmol/mol 
(1.0%) increase in HbA1c 
corresponded to 5.5% (95% 
confidence interval: 3.8-7.3) 
increased risk of adverse 
pregnancy outcome (Nielsen 
et al., 2006) 
Renal disease Yes; there was a 5-year 
incidence of renal 
replacement therapy of 
10.2% in patients with Type 1 
diabetes mellitus recruited to 
the ETDRS trial (Cusick et al., 
2004) 
Yes; 11-mmol/mol (1.0%) 
increment in HbA1c level was a 
significant risk factor of renal 
replacement therapy 
(P ≤ 0.01) (Cusick et al., 
2004); the adjusted hazard 
ratio for microalbuminuria per 
11-mmol/mol (1.0%) increase 
in HbA1c was 1.80 (95% 
confidence interval: 1.54-
2.10) (de Boer et al., 2007) 
Yes Not applicable 
Retinopathy Yes; there was a cumulative 
incidence of 84.1% for any 
retinopathy and 50.2% for 
advanced retinopathy after 
40 years of Type 1 diabetes 
mellitus (Hammes et al., 
2011) 
Yes; an HbA1c level of 
> 58 mmol/mol (7.5%) was a 
significant risk factor for both 
any retinopathy and advanced 
retinopathy (P < 0.0001) 
(Hammes et al., 2011); 
progression of diabetic 
retinopathy also was more 
likely after an increase in 
HbA1c level (Klein et al., 2008) 
Yes Not applicable 
Sleep 
disturbances 
Unclear; limited evidence, 
only 1 study identified (van 
Unclear; limited evidence, 
only 1 study identified (van 
No Insufficient evidence that 
effective diabetes management 
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Complication 
Associated With Type 1 
Diabetes Mellitus 
Associated with Glycaemic 
Control and/or HbA1c 
Selected 
(Yes/No) Reason for Exclusion 
Dijk et al., 2011) Dijk et al., 2011) reduces the risk of Type 1 
diabetes mellitus 
Urinary 
incontinence 
Unclear; limited evidence, 
only 1 study identified (Sarma 
et al., 2009) 
Unclear; limited evidence, 
only 1 study identified (Sarma 
et al., 2009) 
No Insufficient evidence that 
effective diabetes management 
reduces the risk of Type 1 
diabetes mellitus 
Urinary tract 
infections or 
symptoms 
No; sexual activity, rather 
than measures of diabetes 
control and complications, 
was the main risk factor for 
urinary tract infection (Czaja 
et al., 2009) 
No; no association was 
observed between HbA1c 
levels at the DCCT baseline or 
end of study or the year 10 
EDIC examination (urological 
assessment component of the 
EDIC) (Van Den Eeden et al., 
2009) 
No Insufficient evidence that 
effective diabetes management 
reduces the risk of Type 1 
diabetes 
DCCT = Diabetes Control and Complications Trial; EDC = Epidemiology of Diabetes Complications; EDIC = Epidemiology of Diabetes 
interventions and Complications study; ETDRS = Early Treatment of Diabetic Retinopathy Study; HbA1c = glycosylated haemoglobin. 
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Table S3. Probabilities for Type 1 Diabetes Mellitus Complication Events 
Event Probability Source 
Type of first cardiovascular event: conditional upon having a first event 
Death from cardiovascular disease 0.08 Nathan et al., 2005 
Non-fatal acute myocardial infarction 0.20 Nathan et al., 2005 
Silent myocardial infarction 0.24 Nathan et al., 2005 
Revascularisation 0.12 Nathan et al., 2005 
Confirmed angina 0.28 Nathan et al., 2005 
Non-fatal cerebrovascular event 0.07 Nathan et al., 2005 
Subsequent Cardiovascular event annual probability: conditional upon having a 
first eventa 
Death from cardiovascular disease 0.0110 Nathan et al., 2005 
Non-fatal acute myocardial infarction 0.0132 Nathan et al., 2005 
Silent myocardial infarction 0.0176 Nathan et al., 2005 
Revascularisation 0.0685 Nathan et al., 2005 
Confirmed angina 0.0219 Nathan et al., 2005 
Non-fatal cerebrovascular event 0.0825b National Audit Office, 2010 
Death from angina and myocardial infarction 
Angina  
Age, in years: male/female  
35-44 0.0046/0.0025 Hunink et al., 1997c 
45-54 0.0107/0.0062 Hunink et al., 1997c 
55-64 0.0184/0.0120 Hunink et al., 1997c 
65-74 0.0327/0.0251 Hunink et al., 1997c 
75 and over 0.1059/0.0964 Hunink et al., 1997c 
Myocardial infarction: year 1  
Age, in years: first event/subsequent 
event 
 
35-44 0.0154/0.0867 Hunink et al., 1997c 
45-54 0.0336/0.1120 Hunink et al., 1997c 
55-64 0.0730/0.1446 Hunink et al., 1997c 
65-74 0.1587/0.1867 Hunink et al., 1997c 
75 and over 0.2953/0.2953 Hunink et al., 1997c 
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Event Probability Source 
Myocardial infarction: year 2+  
Age, in years: male/female  
35-44 0.0046/0.0025 Weinstein et al., 1987c 
45-54 0.0107/0.0062 Weinstein et al., 1987c 
55-64 0.0184/0.0120 Weinstein et al., 1987c 
65-74 0.0327/0.0251 Weinstein et al., 1987c 
75 and over 0.1059/0.0964 Weinstein et al., 1987c 
Death from revascularisation and death and disability from stroke 
Death from revascularisation 0.263 Mak and Faxon, 2003d 
Death from stroke 0.142 Sacco et al., 1994c,e 
Permanent disability from stroke 0.500 National Audit Office, 2010c 
Death from disabled from stroke 0.0915 Sacco et al., 1994c,e 
Foot ulcer, infection, amputation, and death due to amputation 
Foot ulcer for patients with peripheral 
neuropathy 
0.040 RTI-CDC model (Moss et al., 
1992; Ramsey et al., 1999; 
Reiber et al., 1995)d,f 
Infection for patients with foot ulcer 0.580 Eurodiale Study Group, 2008 
Lower-extremity amputation (defined 
as a non-traumatic lower-extremity 
amputation above or below the knee) 
for patients with peripheral neuropathy 
0.120 Value calibrated so that the 
model reproduced the 
incidence of lower-extremity 
amputation reported by 
Jonasson et al., 2008 (11% at 
age 65 years)g 
Second lower-extremity amputation for 
patients with prior lower-extremity 
amputation 
0.110 Reiber et al., 1995 (for Type 1 
diabetes mellitus and Type 2 
diabetes mellitus) 
Peri-operative death for patients 
undergoing amputation 
0.093 Vamos et al., 2010 
0.348: 30-day 
mortality = 9.3% (all 
individuals admitted to 
National Health Service 
hospitals for non-traumatic 
amputations in 2004-2005 in 
England; data for 376 patients 
with Type 1 diabetes mellitus 
and major lower-extremity 
amputations) 
 10 
Event Probability Source 
End-stage renal disease and death due to end-stage renal disease 
End-stage renal disease for patients 
with microalbuminuria (annual 
probability) 
0.0180 Calibrated with respect to 
Finne et al., 2005 
Death for patients with end-stage renal 
disease 
0.1640 United Kingdom Renal 
Registry, 2010, for Type 1 
diabetes mellitus and Type 2 
diabetes mellitus 
Diabetic-prevalent patient 1-
year survival was 83.6% in 
2009 
Annual rate = 
(–Ln (1 – (1 – 0.836)) / 1) 
Probability = (1 – exp(annual 
rate)) 
Annual probability of blindness for patients with proliferative diabetic retinopathy 
Blindness for patients with proliferative 
diabetic retinopathy 
0.0064 Early Treatment Diabetic 
Retinopathy Study Research 
Group, 1991 (for Type 1 
diabetes mellitus or Type 2 
diabetes mellitus) 
Incidence = 2.6% – 3.7% at 
5 years (midpoint = 3.15% 
assumed) 
Annual rate = 
–Ln(1 – 0.0315) / 5 
Annual probability = 
1 – exp(–annual rate) 
Death from severe hypoglycaemiah and diabetic ketoacidosis 
Death from severe day hypoglycaemia 0.002 Assumptioni 
Death from severe nocturnal 
hypoglycaemia 
0.004 Assumptioni 
Death from diabetic ketoacidosis 0.05 Powers, 2005 
Stillbirth, perinatal mortality, and congenital malformationj 
Stillbirth 0.0210 Jensen et al., 2004 
Perinatal mortality 0.0310 Jensen et al., 2004 
Congenital malformation 0.0500 Jensen et al., 2004 
DCCT = Diabetes Control and Complications Trial; EDIC = Epidemiology of Diabetes interventions and 
Complications study; HbA1c = glycosylated haemoglobin; Ln = natural logarithm; RTI-CDC = Research 
Triangle Institute/Centers for Disease Control and Prevention; UK = United Kingdom. 
Note: Death from other causes was modelled using age- and sex-specific mortality rates for the UK 
general population (Office for National Statistics, 2010). 
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a Calculated as 1 – exp(rate per patient-year). The total patient-years of follow-up for patients with 
any first cardiovascular event was estimated as 451 years, based on the number at risk and the 
cumulative incidence of first cardiovascular event, as reported by Nathan et al., 2005. 
b Probability was derived from data reported by the National Audit Office, 2010, as no subsequent 
non-fatal cerebrovascular events were observed in the DCCT and EDIC studies (35% of patients had a 
subsequent stroke over a period of 5 years after the first stroke; annual rate = –((Ln(1 – 0.35)) / 5); 
probability = (1 – exp(rate)). 
c Not specific to patients with diabetes. 
d Patients with Type 2 diabetes mellitus. 
e Sacco et al., 1994, included 1-month, 1-year, and 5-year transition probabilities. These were 
converted to hazard rates, from which 6-month and 1-year transition probabilities were calculated. 
f Estimates of the incidence of diabetic foot ulcers for the entire Type 2 diabetes mellitus population 
included 2.6% for 1 year (Moss et al., 1992) and 5.8% cumulative incidence for 3 years (Ramsey et 
al., 1999). Most (78%) foot ulcers occurred among patients with neuropathy (Reiber et al., 1995). 
Assuming that the annual incidence rate for all patients with Type 2 diabetes mellitus was 2%, 
patients with neuropathy account for 80% of foot ulcers and that about 40% of patients with Type 2 
diabetes mellitus have neuropathy, the calculation yields an estimated annual incidence of 4% for 
patients with neuropathy. 
g The cumulative probability of having a non-traumatic lower-extremity amputation by age 65 years 
was 11.0% for women with Type 1 diabetes mellitus and 20.7% for men with Type 1 diabetes mellitus 
(Jonasson et al., 2008, based on 31,354 patients with Type 1 diabetes mellitus in the Swedish 
Inpatient Register between 1975 and 2004). Probability calibrated to give a model estimate at default 
settings (timeframe to yield mean age of 65 years) of 11% (the lower end of the reported range was 
selected because the Swedish Registry data included patients from 1975 and incidence was expected 
to decrease with more modern diabetes management). 
h The model was set to a mean age of 33 years, disease duration of 15 years, HbA1c of 72 mmol/mol 
(8.7%), and 49% female. The rate of severe hypoglycaemia per patient-year was based on the DCCT 
and EDIC studies (omitting the conventional treatment group of the DCCT study on the basis that that 
group represented out-of-date treatment). Severe hypoglycaemia (day and nocturnal 
combined) = 11.5 per 100 patient-years (Nathan et al., 2009, reported a range of 6.7-16.4). The 
proportion of all severe hypoglycaemic events that are nocturnal = 55% (The Diabetes Control and 
Complications Trial Research Group, 1993). The model was run to age 40 (7 years), and probability 
was adjusted to reproduce the proportion of all early deaths (age < 40 years) due to hypoglycaemia 
equal to 12%. The probability of death from a nocturnal hypoglycaemic event was assumed to be 
approximately double that for such an event during the day. Standard error was assumed to be 66% 
of the mean, based on the percentage difference in the reported range (66% = (12 – 4) / 12). 
i It is well recognised that the risk of death from hypoglycaemia is very difficult to estimate; the cause 
of death (particularly in cases of “dead in the bed”) is often unclear (Heller, 2008). No data were 
identified from which the probability of death from severe hypoglycaemia could be estimated. 
However, estimates of the proportion of all early deaths that were due to hypoglycaemia have been 
reported. In a review by Heller (2008), estimates of 4%, 7%, and 27% were reported. Patterson et al. 
(2007) reported an estimate of 9% (of 134 deaths, 5 were due to hypoglycaemia and 7 were dead in 
the bed; 12/134 = 9%). The average of these reported values was 12%. Default values for the 
probability of death from severe hypoglycaemic events were estimated using these data as follows: 
The probability of death from a severe day event was assumed to be approximately half that of a 
severe nocturnal event. These probabilities then were adjusted so that the proportion of all deaths 
that were due to hypoglycaemia was equal to 12% of all early deaths (age < 40 years). 
j The number of expected pregnancies during the model’s time horizon was estimated from UK general 
population birth rates, by age (Office for National Statistics, 2009). 
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Table S4. Utility Weights and Costs Associated With Type 1 Diabetes Mellitus Complications (Consistent With the 
CORE Model; Palmer et al., 2004) 
Complicationa 
Utility Weight Cost (£) 
Value Comment Source Value Comment  Source 
No complications 0.814 Utility applied 
annually 
Clarke et al., 
2002 
Not applicable Not applicable Not applicable 
Angina 0.682 Utility applied 
annually 
Clarke et al., 
2002 
Not applicable Not applicable Not applicable 
Angina, year 1 As above for 
angina 
— — 2,623 Annual costs 
due to an 
angina event 
in the first 
year of angina 
Dyer et al., 
2008 
Angina, years 2+ As above for 
angina  
— — 2,196 Annual costs 
in subsequent 
years 
Cameron and 
Bennett, 2009 
Myocardial infarction, 
year of event 
–0.129 Utility 
decrement 
applied 
annually 
Clarke et al., 
2002 
5,093 Annual costs 
due to an 
myocardial 
infarction 
event in the 
year of a first 
or recurrent 
event  
National 
Institute for 
Health and 
Clinical 
Excellence, 
2007 
Myocardial infarction, 
years 2+ post-event 
0.736 Utility applied 
annually 
Clarke et al., 
2002 
573 Annual costs 
in subsequent 
years after an 
event 
National 
Institute for 
Health and 
Clinical 
Excellence, 
2007 
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Complicationa 
Utility Weight Cost (£) 
Value Comment Source Value Comment  Source 
Revascularisation, year 
of event 
–0.129 Utility 
decrement 
applied 
annually 
Assumption 5,000 Annual costs 
due to a 
revascular-
isation event 
in the year of 
a first or 
recurrent 
event 
Assumption 
Revascularisation, 
years 2+ post-event 
0.736 Utility applied 
annually 
Assumption 1,500 Annual costs 
in subsequent 
years after an 
event 
Assumption 
Stroke, year of event –0.181 Utility 
decrement 
applied 
annually 
Clarke et al., 
2002 
9,401 Annual costs 
due to a 
stroke event in 
the year of a 
first or 
recurrent 
event 
National 
Institute for 
Health and 
Clinical 
Excellence, 
2006 
Stroke, years 2+ As above for 
stroke, year of 
event  
— — 2,527 Annual costs 
in subsequent 
years after an 
event 
National 
Institute for 
Health and 
Clinical 
Excellence, 
2006 
Stroke, permanently 
disabled, years 2+ post-
event 
0.545 Utility applied 
annually 
Clarke et al., 
2002 
Not applicable Not applicable Not applicable 
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Complicationa 
Utility Weight Cost (£) 
Value Comment Source Value Comment  Source 
Stroke, death 0.000 — — 8,242 Annual costs 
in the year of 
death due to 
stroke 
Youman et al., 
2003 
Cataract, partially 
sighted (year before 
surgery) 
0.794 Utility applied 
annually 
Palmer et al., 
2004 
0 — Assumption 
Cataract, year of 
surgery 
–0.010 Utility 
decrement 
applied 
annually 
Assumption 833 Annual costs 
in the year of 
cataract 
surgery 
National 
Health 
Service, 2010 
Cataract, years 2+ 
(after operation) 
0.000 — Assumption 383 Annual costs 
in subsequent 
years  
Clarke et al., 
2003 
Neuropathy, year 1 0.624 Utility applied 
annually 
Palmer et al., 
2004 
399 Annual costs 
in the year of 
developing 
neuropathy 
National 
Health 
Service, 2010 
Neuropathy, years 2+ 0.624 Utility applied 
annually 
Palmer et al., 
2004 
399 Annual costs 
in subsequent 
years  
National 
Health 
Service, 2010 
Foot ulcer 0.600 Utility applied 
annually 
Palmer et al., 
2004 
Infected: 
25,858 
Uninfected: 
25,351 
Cost per 
episode 
Ghatnekar et 
al., 2002 
Amputation (year of 
event) 
–0.109 Utility 
decrement 
applied 
annually 
Clarke et al., 
2002 
4,437 Annual costs 
in the year of 
having an 
amputation 
National 
Health 
Service, 2010 
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Complicationa 
Utility Weight Cost (£) 
Value Comment Source Value Comment  Source 
Amputation prosthesis 
(per event) 
Not applicable Not applicable Not applicable 2,234 Costs per 
prosthesis and 
fitting 
Ghatnekar et 
al., 2002 
Post-amputation (years 
2+ post-event) 
0.680 Utility applied 
annually 
Clarke et al., 
2002 
0 Annual cost in 
years after 
amputation 
Palmer et al., 
2004 
Gangrene treatment 
(per event) 
Not applicable Not applicable Not applicable 45,100 Cost per 
episode 
Ghatnekar et 
al., 2002 
Microalbuminuria 0.814 Utility applied 
annually 
Clarke et al., 
2002 
Not applicable Not applicable Not applicable 
End-stage renal diseaseb 
Haemodialysis, year 1 0.490 Utility applied 
annually 
Tengs and 
Wallace, 2000 
37,882 Annual costs 
in the first 
year of 
haemodialysis 
National 
Institute for 
Health and 
Clinical 
Excellence, 
2008 
Haemodialysis, years 
2+ 
0.490 Utility applied 
annually 
Tengs and 
Wallace, 2000 
37,882 Annual costs 
in subsequent 
years 
National 
Institute for 
Health and 
Clinical 
Excellence, 
2008 
Peritoneal dialysis, 
year 1 
0.560 Utility applied 
annually 
Tengs and 
Wallace, 2000 
20,832 Annual costs 
in the first 
year of 
peritoneal 
dialysis 
National 
Institute for 
Health and 
Clinical 
Excellence, 
2008 
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Complicationa 
Utility Weight Cost (£) 
Value Comment Source Value Comment  Source 
Peritoneal dialysis, 
years 2+ 
0.560 Utility applied 
annually 
Tengs and 
Wallace, 2000 
20,832 Annual costs 
in subsequent 
years 
National 
Institute for 
Health and 
Clinical 
Excellence, 
2008 
Renal transplant, year 1 0.762 Utility applied 
annually 
Tengs and 
Wallace, 2000 
22,385 Annual costs 
in the year of 
renal 
transplant 
National 
Institute for 
Health and 
Clinical 
Excellence, 
2008 
Renal transplant, 
years 2+ 
0.762 Utility applied 
annually 
Tengs and 
Wallace, 2000 
7,275 Annual costs 
in subsequent 
years  
National 
Institute for 
Health and 
Clinical 
Excellence, 
2008 
Proliferative diabetic 
retinopathy, year 1 
(laser treatment) 
0.794 Utility applied 
annually 
Palmer et al., 
2004 
290 Annual costs 
in the year of 
development 
of proliferative 
diabetic 
retinopathy 
National 
Health 
Service, 2010 
Proliferative diabetic 
retinopathy, years 2+ 
(after laser treatment) 
0.794 Utility applied 
annually 
Palmer et al., 
2004 
100 Annual costs 
in subsequent 
years  
Assumption 
Blindness, year of onset 0.700 Utility applied 
annually 
Assumption 4,406 Annual costs 
in the first 
year of 
blindness 
Meads and 
Hyde, 2003 
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Complicationa 
Utility Weight Cost (£) 
Value Comment Source Value Comment  Source 
Blindness, following 
years 
0.700 Utility applied 
annually 
Assumption 4,406 Annual costs 
in subsequent 
years of 
blindness 
Meads and 
Hyde, 2003 
Non-severe 
hypoglycaemic event, 
day 
–0.005 Utility 
decrement per 
event, applied 
annually 
Assumption 0 Cost per event Assumption 
Non-severe 
hypoglycaemic event, 
nocturnal 
–0.005 Utility 
decrement per 
event, applied 
annually 
Assumption 0 Cost per event Assumption 
Severe hypoglycaemic 
event, day 
–0.012 Utility 
decrement per 
event, applied 
annually 
Assumption 354 Cost per event National 
Institute for 
Health and 
Clinical 
Excellence, 
2009 
Severe hypoglycaemic 
event, nocturnal 
–0.012 Utility 
decrement per 
event, applied 
annually 
Assumption 354 Cost per event National 
Institute for 
Health and 
Clinical 
Excellence, 
2009 
Diabetic ketoacidosis 
event 
0.000 Utility 
decrement per 
event, applied 
annually 
Assumption 995 Cost per event Ray et al., 
2007 
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Complicationa 
Utility Weight Cost (£) 
Value Comment Source Value Comment  Source 
Average lifetime utility 
for infant with 
congenital malformation 
0.700 Utility applied 
annually 
Assumption Not applicable Not applicable Not applicable 
Average lifetime utility 
for general infant 
0.820 Utility applied 
annually 
Assumption Not applicable Not applicable Not applicable 
a No data describing the uncertainty in cost and utility estimates were available. In the probabilistic sensitivity analysis, the user could select 
from a range of alternative distributional forms and enter estimates of the uncertainty. 
b Of all patients with end-stage renal disease, 44% were assumed to have haemodialysis; 8%, peritoneal dialysis; and 48%, renal 
transplantation (United Kingdom Renal Registry, 2010). 
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Table S5. Mean Net Monetary Benefit and Standard Error as a Function of the 
Number of Individual Patient (First-Order) Simulations 
Number of First-
Order Simulations 
Net Monetary Benefit (at £20,000 per QALY) 
Meana Standard Errora 
Standard Error 
(% of Mean)a 
1,000 £5,079 £2,191 43.1% 
2.000 £7,464 £2,237 30.0% 
5,000 £6,754 £926 13.7% 
10,000 £6,425 £854 13.3% 
20,000 £7,249 £679 9.4% 
50,000 £6,254 £288 4.6% 
100,000 £6,647 £179 2.7% 
QALY = quality-adjusted life-year. 
Note: The individual patient (first-order) simulation was run 5 times for each of the intervals. The 
mean net monetary benefit and standard error were calculated for each simulation; the standard error 
was expressed as a percentage of the mean. 
a Mean and standard error of successive first-order simulation results. 
 
Progression of HbA1c in Patients With Type 1 Diabetes Mellitus 
There is no apparent trend over time in glycated haemoglobin (HbA1c) levels 
in patients with Type 1 diabetes mellitus. Nathan et al. (2009) investigated the 
distribution of HbA1c levels over time in patients participating in the Diabetes 
Control and Complications Trial, the Epidemiology of Diabetes Interventions and 
Complications study, and the Epidemiology of Diabetes Complications study. HbA1c 
levels were relatively stable over the 18 years of follow-up observed in the Diabetes 
Control and Complications Trial, the Epidemiology of Diabetes Interventions and 
Complications study, and the Epidemiology of Diabetes Complications study. 
Therefore, trends in HbA1c levels were included in the model. Probabilities of 
complications were estimated from published cumulative incidence curves and 
adjusted for differences in HbA1c levels among treatments, using published hazard 
ratios or relative risks for the association between HbA1c level and each 
complication. 
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Figure S1. Cost-effectiveness Plane 
 
QALY = quality-adjusted life-year. 
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Figure S2. Cost-effectiveness Acceptability Curve 
 
QALY = quality-adjusted life-year. 
 22 
REFERENCES 
Cameron CG, Bennett HA. Cost-effectiveness of insulin analogues for diabetes 
mellitus. CMAJ 2009 Feb 17; 180(4): 400-7. 
Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 
diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 
2002; 22: 340-9. 
Clarke P, Gray A, Legood R, Briggs A, Holman R. The impact of diabetes-related 
complications on healthcare costs: results from the United Kingdom 
Prospective Diabetes Study (UKPDS Study No 65). Diabetic Med 
2003; 20: 442-50. 
Craig ME, Jones TW, Silink M, Ping YJ. Diabetes care, glycemic control, and 
complications in children with type 1 diabetes from Asia and the Western 
Pacific Region. J Diabetes Complications 2007; 21(5): 280-7. 
Cusick M, Chew EY, Hoogwerf B, Agron E, Wu L, Lindley A, et al. Risk factors for 
renal replacement therapy in the Early Treatment Diabetic Retinopathy Study 
(ETDRS): Early Treatment Diabetic Retinopathy Study report No. 26. 
Kidney Int 2004; 66(3): 1173-9. 
Czaja CA, Rutledge BN, Cleary PA, Chan K, Stapleton AE, Stamm WE. Urinary tract 
infections in women with type 1 diabetes mellitus: survey of female 
participants in the epidemiology of diabetes interventions and complications 
study cohort. J Urol 2009; 181(3): 1129-34. 
de Boer IH, Sibley SD, Kestenbaum B, Sampson JN, Young B, Cleary PA, et al. 
Central obesity, incident microalbuminuria, and change in creatinine 
clearance in the epidemiology of diabetes interventions and complications 
study. J Am Soc Nephrol 2007 Jan; 18(1): 235-43. 
The Diabetes Control and Complications Trial Research Group. The effect of 
intensive treatment of diabetes on the development and progression of long-
term complications in insulin-dependent diabetes mellitus. N Engl J Med 
1993 Sep 30; 329(14): 977-86. 
 23 
Dyer MT, Goldsmith KA, Khan SN, Sharples LD, Freeman C, Hardy I, et al. Clinical 
and cost-effectiveness analysis of an open label, single-centre, randomised 
trial of spinal cord stimulation (SCS) versus percutaneous myocardial laser 
revascularisation (PMR) in patients with refractory angina pectoris: the SPiRiT 
trial. Trials 2008 Jun 30; 9: 40. 
Early Treatment Diabetic Retinopathy Study Research Group (ETDRS). ETDRS 
report number 9. Early photocoagulation for diabetic retinopathy. 
Ophthalmology 1991 May; 98(suppl 5): 766-85. 
Enzlin P, Mathieu C, Van Den Bruel A, Vanderschueren D, Demyttenaere K. 
Prevalence and predictors of sexual dysfunction in patients with type 1 
diabetes. Diabetes Care 2003; 26(2): 409-14. 
Eurodiale Study Group. Diabetic Foot Disease in European Perspective; Results 
From the Eurodiale Study. 2008. Available at 
http://arno.unimaas.nl/show.cgi?fid=10680#page=33 Last accessed 22 April 
2012. 
Färnkvist LM, Lundman BM. Outcomes of diabetes care: a population-based study. 
Int J Qual Health Care 2003 Aug; 15(4): 301-7. 
Finne P, Reunanen A, Stenman S, Groop PH, Gronhagen-Riska C. Incidence of end-
stage renal disease in patients with type 1 diabetes. JAMA 
2005; 294(14): 1782-7. 
Ghatnekar O, Willis M, Persson U. Cost-effectiveness of treating deep diabetic foot 
ulcers with Promogran in four European countries. J Wound Care 
2002 Feb; 11(2): 70-4. 
Grauslund J, Green A, Sjølie AK. Cataract surgery in a population-based cohort of 
patients with type 1 diabetes: long-term incidence and risk factors. Acta 
Ophthalmol 2011 Feb; 89(1): 25-9. 
Hammes HP, Kerner W, Hofer S, Kordonouri O, Raile K, Holl RW. Diabetic 
retinopathy in type 1 diabetes-a contemporary analysis of 8,784 patients. 
Diabetologia 2011; 54(8): 1977-84. 
Heller S. Sudden death and hypoglycemia. Diabet Hypoglycem 
2008 Sep; 1(2): 2-7. 
Hunink MG, Goldman L, Tosteson ANA, Mittleman MA, Goldman PA, Williams LW, 
et al. The recent decline in mortality from coronary heart disease, 
1980-1990. JAMA 1997; 277(7): 535-42. 
 24 
Jacobsen N, Jensen H, Lund-Andersen H, Goldschmidt E. Is poor glycaemic control 
in diabetic patients a risk factor of myopia? Acta Ophthalmol 
2008; 86(5): 510-4. 
Jensen DM, Damm P, Moelsted-Pedersen L, Ovesen P, Westergaard JG, Moeller M, 
et al. Outcomes in type 1 diabetic pregnancies: a nationwide, population-
based study. Diabetes Care 2004 Dec; 27(12): 2819-23. 
Jonasson JM, Ye W, Sparen P, Apelqvist J, Nyren O, Brismar K. Risks of 
nontraumatic lower-extremity amputations in patients with type 1 diabetes: 
a population-based cohort study in Sweden. Diabetes Care 
2008; 31(8): 1536-40. 
Klein BE, Klein R, McBride PE, Cruickshanks KJ, Palta M, Knudtson MD, et al. 
Cardiovascular disease, mortality, and retinal microvascular characteristics in 
type 1 diabetes: Wisconsin epidemiologic study of diabetic retinopathy. Arch 
Intern Med 2004; 164(17): 1917-24. 
Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic 
Study of Diabetic Retinopathy: XXII, the twenty-five-year progression of 
retinopathy in persons with type 1 diabetes. Ophthalmology 
2008 Nov; 115(11): 1859-68. 
Kordonouri O, Hartmann R, Deiss D, Wilms M, Gruters-Kieslich A. Natural course of 
autoimmune thyroiditis in type 1 diabetes: association with gender, age, 
diabetes duration, and puberty. Arch Dis Child 2005; 90(4): 411-4. 
Lauterbach S, Kostev K, Kohlmann T. Prevalence of diabetic foot syndrome and its 
risk factors in the UK. J Wound Care 2010 Aug; 19(8): 333-7. 
Lindsay JR, Kennedy L, Atkinson AB, Bell PM, Carson DJ, McCance DR, et al. 
Reduced prevalence of limited joint mobility in type 1 diabetes in a U.K. clinic 
population over a 20-year period. Diabetes Care 2005; 28(3): 658-61. 
Mak KH, Faxon DP Clinical studies on coronary revascularization in patients with 
type 2 diabetes. Eur Heart J 2003; 24: 1087-103. 
Mantovani RM, Mantovani LM, Dias VM. Thyroid autoimmunity in children and 
adolescents with type 1 diabetes mellitus: prevalence and risk factors. J 
Pediatr Endocrinol Metab 2007; 20(6): 669-75. 
McAlpine RR, Morris AD, Emslie-Smith A, James P, Evans JM. The annual incidence 
of diabetic complications in a population of patients with type 1 and type 2 
diabetes. Diabet Med 2005; 22(3): 348-52. 
 25 
Meads C, Hyde C. What is the cost of blindness? Br J Ophthalmol 
2003 Oct; 87(10): 1201-4. 
Moss SE, Klein R, Klein B. The prevalence and incidence of lower extremity 
amputation in a diabetic population. Arch Intern Med 1992; 152: 610-6. 
Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, et al.; 
Diabetes Control and Complications Trial/Epidemiology of Diabetes 
Interventions and Complications (DCCT/EDIC) Study Research Group. 
Intensive diabetes treatment and cardiovascular disease in patients with 
type 1 diabetes. N Engl J Med 2005 Dec 22; 353(25): 2643-53. 
Nathan DM, Zinman B, Cleary PA, Backlund JY, Genuth S, Miller R, et al. Modern-
day clinical course of type 1 diabetes mellitus after 30 years’ duration: the 
Diabetes Control and Complications Trial/Epidemiology of Diabetes 
Interventions and Complications and Pittsburgh epidemiology of diabetes 
complications experience (1983-2005). Arch Intern Med 
2009; 169(14): 1307-16. 
National Audit Office. Progress in Improving Stroke Care. 2010. Available at 
http://www.nao.org.uk/publications/0910/stroke.aspx Last accessed 21 April 
2012. 
National Health Service, Department of Health. NHS Reference Costs, 2008-2009. 
2010. Available at 
http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsP
olicyAndGuidance/DH_111591 Last accessed 26 March 2012. 
National Institute for Health and Clinical Excellence. Clinical Guideline 48. MI: 
Secondary Prevention. 2007. Available at http://guidance.nice.org.uk/CG48 
Last accessed 26 March 2012. 
National Institute for Health and Clinical Excellence. Clinical Guideline 73. Chronic 
Kidney Disease. 2008. Available at http://guidance.nice.org.uk/CG73 Last 
accessed 26 March 2012. 
National Institute for Health and Clinical Excellence. Clinical Guideline 87. Type 2 
Diabetes—Newer Agents (Partial Update of CG66). 2009. Available at 
http://guidance.nice.org.uk/CG87 Last accessed 26 March 2012. 
National Institute for Health and Clinical Excellence. Technology Appraisal 94. 
Cardiovascular disease—Statins. 2006. Available at 
http://guidance.nice.org.uk/TA94 Last accessed 26 March 2012. 
 26 
Nielsen GL, Møller M, Sørensen HT. HbA1c in early diabetic pregnancy and 
pregnancy outcomes: a Danish population-based cohort study of 573 
pregnancies in women with type 1 diabetes. Diabetes Care 
2006 Dec; 29(12): 2612-6. 
Office for National Statistics. Birth Statistics 2008, Series FM1 No.37. 2009. 
Available at http://www.ons.gov.uk/ons/rel/vsob1/birth-statistics--england-
and-wales--series-fm1-/no--37--2008/index.html Last accessed 9 February 
2012. 
Office for National Statistics. Death registrations summary tables, England and 
Wales. 2010. Available at http://www.ons.gov.uk/ons/publications/re-
reference-tables.html?edition=tcm%3A77-227638 Last accessed 12 February 
2012. 
Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, et al. The CORE 
Diabetes Model: projecting long-term clinical outcomes, costs and cost-
effectiveness of interventions in diabetes mellitus (types 1 and 2) to support 
clinical and reimbursement decision making. Curr Med Res Opin 
2004; 20(suppl 1): S5-26. 
Patterson CC, Dahlquist G, Harjutsalo V, Joner G, Feltbower RG, Svensson J, et al. 
Early mortality in EURODIAB population-based cohorts of type 1 diabetes 
diagnosed in childhood since 1989. Diabetologia 2007; 50(12): 2439-42. 
Pavlovic MD, Milenkovic T, Dinic M, Misovic M, Dakovic D, Todorovic S, et al. The 
prevalence of cutaneous manifestations in young patients with type 1 
diabetes. Diabetes Care 2007; 30(8): 1964-7. 
Pedersen-Bjergaard U, Pramming S, Heller SR, Wallace TM, Rasmussen AK, 
Jørgensen HV, et al. Severe hypoglycaemia in 1076 adult patients with type 
1 diabetes: influence of risk markers and selection. Diabetes Metab Res Rev 
2004 Nov-Dec; 20(6): 479-86. 
Powers AC. Diabetes mellitus. In: Kasper DL, Braunwald E, Hauser S, Longo D, 
Jameson JL, Fauci AS. Harrison’s Principles of Internal Medicine. 16th Edition. 
New York: McGraw-Hill, 2005: 2152-80. 
Ramsey SD, Newton K, Blough D, McCulloch DK, Sandhu N, Reiber GE, et al. 
Incidence, outcomes, and cost of foot ulcers in patients with diabetes. 
Diabetes Care 1999; 22(3): 382-7. 
 27 
Ray JA, Boye KS, Yurgin N, Valentine WJ, Roze S, McKendrick J, et al. Exenatide 
versus insulin glargine in patients with type 2 diabetes in the UK: a model of 
long-term clinical and cost outcomes. Curr Med Res Opin 
2007 Mar; 23(3): 609-22. 
Reiber GE, Boyko EJ, Smith DG. Lower extremity foot ulcers and amputations in 
diabetes. In: National Diabetes Data Group, editors. Diabetes in America. 
2nd Edition. Bethesda: National Institutes of Health, National Institute of 
Diabetes and Digestive and Kidney Diseases, 1995:409-28. 
Sacco RL, Shi T, Zamanillo MC, Kargman DE. Predictors of mortality and 
recurrence after hospitalized cerebral infarction in an urban community: the 
Northern Manhattan Stroke Study. Neurology 1994; 44: 626-34. 
Sahakyan K, Klein BE, Lee KE, Myers CE, Klein R. The 25-year cumulative 
incidence of lower extremity amputations in people with type 1 diabetes. 
Diabetes Care 2011; 34(3): 649-51. 
Sarma AV, Kanaya A, Nyberg LM, Kusek JW, Vittinghoff E, Rutledge B, et al. Risk 
factors for urinary incontinence among women with type 1 diabetes: findings 
from the epidemiology of diabetes interventions and complications study. 
Urology 2009; 73(6): 1203-9. 
Singh R, Gamble G, Cundy T. Lifetime risk of symptomatic carpal tunnel syndrome 
in type 1 diabetes. Diabet Med 2005; 22(5): 625-30. 
Targher G, Bertolini L, Chonchol M, Rodella S, Zoppini G, Lippi G, et al. Non-
alcoholic fatty liver disease is independently associated with an increased 
prevalence of chronic kidney disease and retinopathy in type 1 diabetic 
patients. Diabetologia 2010; 53(7): 1341-8. 
Tengs TO, Wallace A. One thousand health-related quality-of life estimates. Med 
Care 2000; 38: 583-637. 
United Kingdom National Diabetes Audit. Executive Summary 2009-2010. 2010. 
Available at 
http://www.ic.nhs.uk/webfiles/Services/NCASP/Diabetes/200910%20annual
%20report%20documents/National_Diabetes_Audit_Executive_Summary_20
09_2010.pdf Last accessed 11 February 2012. 
United Kingdom Renal Registry, The Renal Association. The Thirteenth Annual 
Report. December 2010. Available at 
http://www.renalreg.com/Reports/2010.html Last accessed 21 April 2012. 
 28 
Vamos EP, Bottle A, Majeed A, Millett C. Trends in lower extremity amputations in 
people with and without diabetes in England, 1996-2005. Diabetes Res Clin 
Pract 2010; 87(2): 275-82. 
Van Den Eeden SK, Sarma AV, Rutledge BN, Cleary PA, Kusek JW, Nyberg LM, et 
al. Effect of intensive glycaemic control and diabetes complications on lower 
urinary tract symptoms in men with type 1 diabetes: Diabetes Control and 
Complications Trial/Epidemiology of Diabetes Interventions and 
Complications (DCCT/EDIC) study. Diabetes Care 2009; 32(4): 664-70. 
van Dijk M, Donga E, van Dijk JG, Lammers GJ, van Kralingen KW, Dekkers OM, et 
al. Disturbed subjective sleep characteristics in adult patients with long-
standing type 1 diabetes mellitus. Diabetologia 2011; 54(8): 1967-76. 
Weinstein MC, Coxson PG, Williams LW, Pass TM, Stason WB, Goldman L. 
Forecasting coronary heart disease incidence, mortality, and cost: the 
Coronary Heart Disease Policy Model. Am J Public Health 
1987; 77(11): 1417-26. 
World Health Organization. Definition, diagnosis, and classification of diabetes 
mellitus and its complications. Report of a WHO consultation. Part 1: 
diagnosis and classification of diabetes mellitus. Geneva, Switzerland: World 
Health Organization; 1999. 
Youman P, Wilson K, Harraf F, Kalra L. The economic burden of stroke in the 
United Kingdom. Pharmacoeconomics 2003; 21(suppl 1): 43-50. 
 
